Uganda - English - National Drug Authority

fresenius kabi south africa (pty) limited - poly (o-2-hydroxyethyl) starch (hes 130/0.4) - parenteral ordinary infusion vials/bottles - 60 g/1000 ml

Kenya - English - Pharmacy and Poisons Board

fresenius kabi south africa (pty) limited stand 7 growthpoint park 2 tonetti street hlafway - poly (o-2-hydroxyethyl) starch - solution for infusion - 60 g/1000 ml - blood substitutes and plasma protein fractions

Namibia - English - Namibia Medicines Regulatory Council

fresenius kabi manufacturing (sa) (pty) ltd - hetastarch - infusion (pareneral) - each 1000ml of solution contains: hetastarch 60.0g

Ireland - English - HPRA (Health Products Regulatory Authority)

fresenius kabi limited - poly(o-2-hydroxyethyl)starch, sodium acetate trihydrate, sodium chloride, potassium chloride, magnesium chloride hexahydrate - solution for infusion - 6 per cent - blood substitutes and plasma protein fractions

Ireland - English - HPRA (Health Products Regulatory Authority)

fresenius kabi limited - poly(o-2-hydroxyethyl)starch, sodium acetate trihydrate, sodium chloride, potassium chloride, magnesium chloride hexahydrate - solution for infusion - 6 per cent - blood substitutes and plasma protein fractions

New Zealand - English - Medsafe (Medicines Safety Authority)

fresenius kabi new zealand limited - hydroxyethyl starch 130/0.4 60 g/l; magnesium chloride hexahydrate 0.3 g/l;  ; potassium chloride 0.3 g/l; sodium acetate trihydrate 4.63 g/l;  ; sodium chloride 6.02 g/l;  ;  ;   - solution for infusion - 6 % - active: hydroxyethyl starch 130/0.4 60 g/l magnesium chloride hexahydrate 0.3 g/l   potassium chloride 0.3 g/l sodium acetate trihydrate 4.63 g/l   sodium chloride 6.02 g/l       excipient: hydrochloric acid sodium hydroxide water for injection - treatment of hypovolaemia due to acute blood loss when chrystlloids alone are not considered sufficient. the use of volulyte is not a substitute for the appropriate use of packed red blood cells or fresh frozen plasma.